EJC Skin Cancer最新文献

{"title":"Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations","authors":"Sophia Kreft ,&nbsp;Tommaso Bosetti ,&nbsp;Rebecca Lee ,&nbsp;Paul Lorigan","doi":"10.1016/j.ejcskn.2025.100285","DOIUrl":"10.1016/j.ejcskn.2025.100285","url":null,"abstract":"<div><div>Immunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some. The recent approval of nivolumab in combination with relatlimab (nivolumab-relatlimab) added a third immunotherapy option for first-line treatment for advanced melanoma. Nivolumab-relatlimab has shown greater efficacy compared to single-agent nivolumab and has fewer unacceptable side effects compared to the combination of ipilimumab and nivolumab (ipilimumab-nivolumab). However, the lack of both long-term follow-up data and direct comparison with ipilimumab-nivolumab raises uncertainty about where to position nivolumab-relatlimab in clinical practice. Since most patients who respond to combination ipilimumab-nivolumab also respond to nivolumab-relatlimab, and many to single-agent anti-programmed death-1 (PD-1) monotherapy, the challenge is to identify the subgroup of patients who need ipilimumab-nivolumab and would not achieve similar benefits from less toxic alternatives. This review discusses the available data on efficacy of the three approved first-line immunotherapies (single-agent anti-PD-1, nivolumab-relatlimab or ipilimumab-nivolumab) and their value in distinct population groups to help guide clinical decisions.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100285"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143323472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved prognostic guidance with 31-gene expression profiling for patients with stage IIB-IIC cutaneous melanoma: a SEER collaboration","authors":"B. Moody ,&nbsp;B. Martin ,&nbsp;A. Hanson ,&nbsp;V. Petkov","doi":"10.1016/j.ejcskn.2025.100387","DOIUrl":"10.1016/j.ejcskn.2025.100387","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100387"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Italian interim analysis of the multinational, post-authorisation safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma: focus on time to onset of adverse events","authors":"L. Scarpato ,&nbsp;P.A. Ascierto ,&nbsp;M. Scalvenzi ,&nbsp;A. Villani ,&nbsp;P. Bossi ,&nbsp;A. Alberti ,&nbsp;V. De Giorgi ,&nbsp;L. Licitra ,&nbsp;M.C. Fargnoli ,&nbsp;P. Savoia ,&nbsp;M. Guida ,&nbsp;F. Spagnolo ,&nbsp;F. De Galitiis ,&nbsp;I. Stanganelli ,&nbsp;K. Peris","doi":"10.1016/j.ejcskn.2025.100335","DOIUrl":"10.1016/j.ejcskn.2025.100335","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100335"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143748123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metatypical Metastatic Basal Cell Carcinoma Treated with Vismodegib: Report of Two Cases","authors":"D. Amarillo,&nbsp;V. Lemes,&nbsp;G. Krygier","doi":"10.1016/j.ejcskn.2025.100322","DOIUrl":"10.1016/j.ejcskn.2025.100322","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100322"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143748340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the common mutational landscape in cutaneous melanoma and pancreatic cancer","authors":"F. Venturi ,&nbsp;E. Broseghini ,&nbsp;M. Ferracin ,&nbsp;E. Dika","doi":"10.1016/j.ejcskn.2025.100351","DOIUrl":"10.1016/j.ejcskn.2025.100351","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100351"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of long-term survivors with metastatic uveal melanoma and liver metastases diagnosed between 2005 and 2021","authors":"J. Laukuf ,&nbsp;L. Wiens ,&nbsp;G. Grözinger ,&nbsp;H. Dittmann ,&nbsp;K. Thiel ,&nbsp;U. Leiter ,&nbsp;T. Amaral ,&nbsp;L. Nanz ,&nbsp;L. Flatz ,&nbsp;M. Reitmajer ,&nbsp;A. Forschner","doi":"10.1016/j.ejcskn.2025.100385","DOIUrl":"10.1016/j.ejcskn.2025.100385","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100385"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study","authors":"Clara Mayo de las Casas ,&nbsp;Eloisa Jantus-Lewintre ,&nbsp;Sebastian Ortiz Reina ,&nbsp;Ana Drozdowskyj ,&nbsp;Pablo Cerezuela-Fuentes ,&nbsp;Jose Luis Manzano ,&nbsp;Pablo Ayala de Miguel ,&nbsp;Ana Arance Fernandez ,&nbsp;Miguel Angel Berciano-Guerrero ,&nbsp;Almudena Garcia-Castaño ,&nbsp;Teresa Puertolas ,&nbsp;Guillermo Crespo ,&nbsp;Maria Quindos-Varela ,&nbsp;Juan Francisco Rodriguez-Moreno ,&nbsp;Alfonso Berrocal ,&nbsp;Eva Muñoz-Couselo ,&nbsp;Enrique Espinosa ,&nbsp;Joselyn Valarezo ,&nbsp;Susana Muñoz ,&nbsp;Silvia Calabuig-Fariñas ,&nbsp;Maria Gonzalez-Cao","doi":"10.1016/j.ejcskn.2025.100738","DOIUrl":"10.1016/j.ejcskn.2025.100738","url":null,"abstract":"<div><h3>Background</h3><div>BRAF p.V600 mutation is the most frequent molecular driver alteration in melanoma. Detection of BRAF mutations in circulating-free DNA (cfDNA) reflects the shedding of tumor DNA and offers a potential non-invasive biomarker for disease monitoring and prognosis. However, the lack of standardized methodologies and inter-assay variability hinders its clinical implementation.</div></div><div><h3>Methods</h3><div>The sensitivity, agreement and concordance of seven <em>BRAF</em> mutation detection assays were assessed across four laboratories. <em>BRAF</em> p.V600 mutation in pretreatment plasma samples was analyzed in 51 patients diagnosed with advanced stage melanoma using two digital PCR-based assays (droplet digital PCR -ddPCR- Bio-Rad and microfluidic digital PCR -Absolute Q, ThermoFisher Scientific-), three RT-PCR based assays (Idylla®, Cobas®, PNA-Q-PCR) and two NGS based assays (Oncomine™ Pan-Cancer Cell-Free Assay and Illumina Platforms).</div></div><div><h3>Results</h3><div>digital PCR-based assays and Cobas® exhibited the highest sensitivity (51.0 %), followed by NGS Illumina® (45.1 %), Oncomine NGS / PNA-Q-PCR (43.1 %) and Idylla® (37.2 %). Results of different techniques showed a moderate to strong agreement, except for the comparison of Cobas with Idylla that was poor (Kappa=0.57). There was near-perfect agreement on detection of <em>BRAF</em> mutation between both NGS platforms and the NGS Illumina® with PNA-Q-PCR (Kappa = 0.92). Concordance of the quantitative results in terms of mutant allele frequency was near-perfect between NGS Illumina and ddPCR Bio-Rad assays (ICC = 0.99).</div></div><div><h3>Conclusions</h3><div>Our study demonstrates substantial agreement among multiple cfDNA <em>BRAF</em> mutation detection assays, particularly between NGS and digital PCR assays. These findings support the potential utility of different techniques for BRAF testing in cfDNA.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100738"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144739604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant and neoadjuvant immunotherapy for acral and mucosal melanoma","authors":"Takaya Komori ,&nbsp;Shigeru Koizumi ,&nbsp;Sadao Inoue ,&nbsp;Maiko Yamaura ,&nbsp;Yuri Murayama ,&nbsp;Atsushi Otsuka ,&nbsp;Yasuhiro Nakamura","doi":"10.1016/j.ejcskn.2024.100277","DOIUrl":"10.1016/j.ejcskn.2024.100277","url":null,"abstract":"<div><div>Significant advancements have been made in the treatment of cutaneous melanoma over the past decade, particularly with the effectiveness of immune checkpoint inhibitors (ICIs) in advanced and adjuvant stages. However, the efficacy of ICIs for non-Caucasian populations and the rare clinical subtypes acral melanoma (AM) and mucosal melanoma (MM), has gradually been recognized to be lower in the advanced setting than cutaneous melanoma, suggesting that the use of ICIs in treating AM and MM need careful consideration in terms of ethnic and disease-specific factors to optimize outcomes in the adjuvant and neoadjuvant setting. However, the efficacy of adjuvant and neoadjuvant ICIs for AM and MM remains unclear. Therefore, in this review, we discussed the latest study updates on adjuvant and neoadjuvant therapies for AM and MM, focusing on anti-PD-1 antibody-based therapies. Our findings revealed that the efficacy of adjuvant and neoadjuvant therapy with anti-programmed death-1 receptor (anti-PD-1) antibody-based therapies for cutaneous melanoma is promising; however, their effectiveness varies according to ethnicity and melanoma subtype. There are several ongoing clinical trials on adjuvant and neoadjuvant therapies targeting AM or MM, which will provide the future perspectives of the strategy in the adjuvant and neoadjuvant settings for these rare melanoma subtypes.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100277"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143183584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient and physician-reported outcomes with tirbanibulin 1% ointment for actinic keratosis under conditions close to routine clinical practice in Spain and Italy (TIRBASKIN study)","authors":"Y. Gilaberte ,&nbsp;O. Yélamos ,&nbsp;J. Cañueto ,&nbsp;C. Serra-Guillén ,&nbsp;A. Conti ,&nbsp;F. Pajuelo ,&nbsp;A. Lecchi ,&nbsp;V. Cappello ,&nbsp;B. Kostov ,&nbsp;M. Romanelli","doi":"10.1016/j.ejcskn.2025.100300","DOIUrl":"10.1016/j.ejcskn.2025.100300","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100300"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","authors":"Oliver John Kennedy ,&nbsp;Nina Glassee ,&nbsp;Michal Kicinski ,&nbsp;Emanuel Bührer ,&nbsp;Sara Valpione ,&nbsp;Sara Gandini ,&nbsp;Stefan Suciu ,&nbsp;Christian U. Blank ,&nbsp;Georgina V. Long ,&nbsp;Victoria G. Atkinson ,&nbsp;Stéphane Dalle ,&nbsp;Andrew M. Haydon ,&nbsp;Andrey Meshcheryakov ,&nbsp;Adnan Khattak ,&nbsp;Matteo S. Carlino ,&nbsp;Shahneen Sandhu ,&nbsp;James Larkin ,&nbsp;Susana Puig ,&nbsp;Paolo A. Ascierto ,&nbsp;Piotr Rutkowski ,&nbsp;Mario Mandala","doi":"10.1016/j.ejcskn.2025.100284","DOIUrl":"10.1016/j.ejcskn.2025.100284","url":null,"abstract":"<div><h3>Background</h3><div>Metabolic conditions, such as obesity and type 2 diabetes mellitus (T2DM), cause changes in immune function that may influence immunotherapy effectiveness and immune-related adverse events (irAEs).</div></div><div><h3>Objectives</h3><div>To investigate the prognostic and predictive effects of BMI and T2DM and investigate the effect of BMI on toxicity using data from the EORTC 1325/KEYNOTE-054 randomised controlled trial.</div></div><div><h3>Methods</h3><div>Pembrolizumab (n = 514) was administered every three weeks for 1 year and prolonged recurrence-free survival (RFS) compared to placebo (n = 505) among patients with resected high-risk stage III melanoma. Here, we used multivariate Cox regression to investigate associations of BMI and T2DM with RFS, and Fine and Gray regression to investigate the association of BMI with the cumulative incidence of irAEs.</div></div><div><h3>Results</h3><div>BMI had an approximately U-shaped association with RFS (p = 0.004) in both treatment arms combined. The RFS hazard ratios (HR)s for BMIs of 20, 30 and 35 kg/m² (compared to 25 kg/m²) were 1.28 (95 % CI 1.05–1.56), 0.96 (95 % CI 0.88–1.06) and 1.14 (95 % CI 0.98–1.34), respectively. There was no evidence that BMI was associated with pembrolizumab effectiveness (p = 0.20) or the cumulative incidence of irAEs (p = 0.74). T2DM was not associated with RFS (HR 1.01, 95 % CI 0.73–1.40) in both arms combined and there was no evidence of an association between T2DM and pembrolizumab effectiveness (p = 0.83). In summary, in patients with resected high-risk stage III melanoma, BMI was associated with RFS in patients overall and within each treatment group.</div></div><div><h3>Conclusions</h3><div>BMI appeared to confer a prognostic effect but was not predictive of pembrolizumab effectiveness regarding RFS. BMI was not related to irAEs among patients receiving pembrolizumab, while T2DM was not associated with RFS irrespective of treatment.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100284"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143436895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}